Innate Pharma S.A. (IPHA)
Nasdaq: IPHA · Biological Products, (No Diagnostic Substances) · Marseille · filing with the SEC since 2014
Who owns Innate Pharma S.A.
As filed with the SECHolders of 5% or more
3
Sanofi holds 9.05% of Ordinary Shares, Euro 0.05 nominal value per share, as its SCHEDULE 13G/A filed Apr 29, 2025 says.
Directors and officers
0
report now, of 0 people on the record since . Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Sanofi
SCHEDULE 13G/A · filed Apr 29, 2025 · Ordinary Shares, Euro 0.05 nominal value per share · 9.05% in Apr 29, 2025
AstraZeneca PLC
SCHEDULE 13D/A · filed Feb 6, 2026 · Ordinary Shares, EUR0.05 nominal value per share
Caisse des depots et consignations
SCHEDULE 13D/A · filed May 7, 2025 · Ordinary Shares, nominal value EUR0.05 per share
Novo-Nordisk A/S
SCHEDULE 13G/A · filed Jun 22, 2026 · Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) · reported falling below 5%, from 5.03% in Apr 10, 2026
What IPHA reports owning in othersstakes of 5% or more, and other ties
Innate Pharma S.A. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.